Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

LEXINGTON, Mass. and LONDON, Oct. 02, 2017 -- Nightstar Therapeutics plc (“Nightstar” or the “Company”) (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the closing of its previously announced initial public offering in the United States of 6,164,000 American Depositary Shares (“ADSs”) representing 6,164,000 ordinary shares, at an initial public offering price of $14.00, which includes an additional 804,000 ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs.  Aggregate net proceeds to the Company, after underwriting discounts and commissions and estimated offering expenses payable by the Company, will be approximately $76.9 million. All of the ADSs were offered by Nightstar.

Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Securities Inc. and Chardan acted as co-managers.

The offering was made only by means of a prospectus.  A copy of the prospectus relating to the offering was filed with the U.S. Securities and Exchange Commission and may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or by email at [email protected]; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, or by telephone at (800) 414-3627, or by email at [email protected].

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission.  This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.

Contact:

Senthil Sundaram, Chief Financial Officer
[email protected] 

Alicia Davis, THRUST IR
910-620-3302
[email protected]